>>> deutsche Bank :Reports Q1 Net €1.9B v €2.3B; Pretax profit €1.5B, -12% y/y;

Reports Q1 Net €1.9B v €2.3B; Pretax profit €1.5B, -12% y/y; Rev €10.4B, +24% y/y 

- Core tier 1 capital ratio fully loaded 11.7% v 11.7% q/q
- Leverage ratio 3.4% v 3.5% q/q- After tax ROE 3.1% v 7.9% y/y
- Loan loss provisions €218M v €246M y/y
- Global transaction banking pretax €409M v €356M y/y
- Deutsche Asset & Wealth management pretax €291M v €166M y/y
- Corporate banking and Securities pretax €643M v €1.44B y/y
- Private Business and clients pretax €536M v €475M y/y

- Co-CEOs: In the first quarter 2015, revenues were close to record levels, reflecting the strength of our franchise across all our core businesses. Profits were impacted by litigation expenses of €1.5B, primarily reflecting the banks definitive settlement with US and UK authorities relating to interbank offered rates (IBOR) and bank levy charges of €561 million.... Core Bank adjusted IBIT of €3.5B was the best since we launched Strategy 2015+ in 2012, reflecting both revenue strength and discipline in our adjusted cost base. In CB&S, Debt Sales & Trading revenues were the best since eight quarters and Equity Sales & Trading revenues the best since 2008, driven by strong client activity, robust markets and a normalization of market volatility after recent historic lows. Both PBC and GTB overcame the challenge of persistent low interest rates to achieve near record quarterly profits. Deutsche AWM grew revenues significantly, increased pre-tax profits by 75% year-on-year, and attracted €17B of net new money inflows.... These results provide a snapshot of a Deutsche Bank which is much stronger than when we began our journey in 2012. We have delivered robust operating performance despite tight resource discipline and significant investments in regulatory compliance. We have significantly strengthened our capital position. We embark on the next phase of our strategy from a position of strength. 

>>> Barron's summary: Positive on AMZN, TCO, ESL; Cautious on ATHN, WWE, QCOM

Barron's summary: Positive on AMZN, TCO, ESL; Cautious on ATHN, WWE, QCOM 

Cover story: In the latest Barrons Big Money poll, a record 50% of respondents say they are neutral about the stock markets prospects through year-end, the highest such reading since spring 2005, and a sharp increase from last falls 31%.

Tech Trader: Positive on AMZN: Amazon Web Services division turns out to be very profitable, making up 7% of revenue but 37% of profit; companys decision to release financial information about it should ease Wall Street concerns.

Trader: A strong Nasdaq and decent earnings reports could be the catalyst that lifts the broader market out of its rut, says Brad McMillan of Commonwealth Financial; Cautious on ATHN: Though shares have tumbled 16% this year, they remain richly valued and further weakness is possible as company faces an increasingly competitive and even saturated market; Cautious on WWE: Total subscriptions continue to rise, but the day rate of new subscribers has plummeted after the initial burst in 2014, and shares could head lower if growth falls short of expectations.

Features: 1) Cautious on QCOM: Jana Partners call for a restructuring--including cutting R&D costs, buying back shares, and splitting off chipset business--could lift shares to about $90, but a spinoff would complicate intellectual property issues; 2) Positive on Anglo American: After years of poor performance, mining group is improving cost controls, boosting operating efficiency, and selling underperforming assets, which could send shares up 20% during the next year; 3) Positive on TCO: Firm trades at the widest discount to estimated net asset value of any major mall-focused real estate investment trust, but that gap could soon close as new malls in development come on-line. 

Small Caps: Positive on ESL: Major changes are under way at airline, which has been restructuring to become a leaner more cohesive company, and changes could benefit investors as soon as next year. 

Profile: Disque Deane Jr., Matt Diserio, and Marc Robert of Water Asset Management, which seems assured of continued upside as the urgency of global water needs grows (picks: Suez Environnement, Aqua America, Northwest Pipe; pans: Sabesp, Copasa).

Interview: Bill Priest and David Pearl, co-chief investment officers, Epoch Investment Partners, who focus on shareholder yield, or the way companies allocate capital (Pearls picks: HXL, MSFT, MS; Priests picks: Accor, Airbus Group, WPP). 

Follow-Up: Positive on CMCSA: Shareholders should be happy about scuttled TWC merger, since it opens up the possibility for buybacks or smaller deals that would be more beneficial; Positive on HD: Company has rallied since just more than a year ago, but its run doesnt seem to be over yet, and it should continue to benefit from a mild resurgence in new construction and higher spending on remodeling. 

European Trader: Upcoming U.K. elections are among the most unpredictable in history and the results are likely to have ramifications across Britain, the EU, and markets; A conservative win would benefit St. James Place and Prudential, while BT Group should do well regardless because both parties recognize the importance of advanced 4G and fiber infrastructure. 

Asian Trader: Pakistans prospects look brighter today than they have in a long time, and are now similar to those of India, though investing there isnt for the faint-hearted.

Emerging Markets: Negative on PBR: Shares of troubled Brazilian oil major have made gains, making the stock pretty fully valued in light of the potential for more problems--and investors should steer clear. 

Commodities: Iron ore prices, which have recently steadied at around $50 a metric ton, are expected to continue to slide as supplies keep piling up.

Streetwise: Positive on AFL, CMI, ORCL: Shares are among those on the Standard & Poors High Quality Index that are cheap, high-quality, and high-beta, with stable earnings, strong balance sheets, and sustainable dividends.

FT : No end in sight to wave of pharma dealmaking



No end in sight to wave of pharma dealmaking


    Pharma 2
    Since the start of last year, pharmaceuticals companies have agreed $462bn of mergers and acquisitions — greater than the gross domestic product of Austria.
    This record wave of dealmaking has swept every corner of the industry, from the household names of big pharma to up-and-coming biotech companies to the lower-profile makers of generic and over-the-counter drugs.
    This latter category produced the latest deal activity last week when Teva of Israel launched a $43bn hostile bid for its US-based, Dutch-registered rival Mylan. If completed, the combined group would have annual revenues of about $30bn — placing it above AstraZeneca among the world’s top 10 drugmakers.
    Mylan has so far resisted Teva’s advances, preferring instead to pursue its own $33bn hostile bid for Perrigo, a Dublin-based generic drugmaker, just two months after completing a $5.3bn acquisition of products from Abbott Laboratories of the US.
    This blur of deals and attempted deals involving Mylan is the latest subplot in the wider M&A drama gripping the industry. What is driving the frenzy? Jeremy Levin, former chief executive of Teva, says the most important factor has been financial rather than strategic. “Capital costs have come down so the return on investment from buying assets is higher than in the past.”
    This is true for all industries in an era of ultra-low interest rates, but Mr Levin, now chief executive of US biotech company Ovid Therapeutics, says other catalysts have made drugmakers especially eager to take advantage. For generic manufacturers such as Teva, Mylan and Actavis, the pressure has come from the rise of lower-cost Indian rivals such as Sun Pharma and Cipla.
    Actavis has responded by shifting towards higher-value branded products, culminating in its $72.7bn acquisition of Allergan, maker of Botox, last November. Teva’s proposed tie-up with Mylan would double down on generics, but with the aim of saving $2bn a year and creating more firepower to chase Actavis up the value chain.
    This prolific dealmaking has thrust these previously second-tier drugmakers — Valeant is another — towards the top table of global pharma, and investors are cheering them on. Shares in Mylan had risen by more than a third over the past year even before Teva’s approach, compared with 16 per cent for the broader sector.
    This insurgency is increasing pressure on the biggest pharma groups — such as PfizerRoche and Novartis — after years of sluggish returns from their much heavier investment in research and development.
    In the past, some of these stalwarts might have looked to join forces. That was what happened in the last big round of consolidation, around the turn of the millennium, through Glaxo Wellcome’s merger with SmithKline Beecham and Pfizer’s with Warner-Lambert and Wyeth. But these huge deals largely failed to boost R&D and, with the exception of Pfizer’s failed bid for AstraZeneca last year, the top groups have since steered clear of megamergers.
    Pharma 1
    Instead, big pharma has sought to buy growth off-the-shelf through the acquisition of promising new medicines from smaller biotech companies. Among the most recent deals was AbbVie’s $21bn takeover last month of Pharmacyclics, maker of a fast-growing blood cancer drug.
    Mr Levin says the maturing science of the biotech sector has been an important driver behind the M&A boom, as big drugmakers scramble to refill their R&D pipelines after the heavy patent expiries of recent years.
    The US Food and Drug Administration last year approved 41 new drugs — the highest tally for 18 years and the second-highest on record. Hepatitis C, cancer and heart disease are among the areas seeing big advances, much of it stemming from smaller biotech companies.
    “M&A provides the fuel for this innovation by delivering a return for the people who funded it and this can then be recycled into further innovation,” says Mr Levin. “Deals are a healthy part of the biotech ecosystem.”
    At the same time as they hunt fresh growth, big groups have been shedding non-core assets in an effort to become more streamlined. Novartis and GlaxoSmithKline, for example, last month completed a $20bn asset swap in which they each offloaded sub-scale businesses and beefed up areas of strength.
    Dan Mahony, healthcare fund manager at Polar Capital, says that, while the deals of the past year have come in many shapes and sizes, they all have a common motivation: pressure on the industry to become more efficient in the face of rising demand from an ageing population.
                                                                             

    Drugmakers are wearily accustomed to wrangling with cash-strapped public health systems in Europe over pricing. But these tensions are increasingly evident in the US too, as insurers and care providers show signs of finally trying to squeeze more value from the 18 per cent of gross domestic product spent on healthcare.
    Mr Mahony points to last month’s $13bn deal between UnitedHealth, the insurer, and Catamaran, a prescription management company, to argue that the hitherto fragmented US healthcare market is consolidating — creating more leverage over drug pricing. “Healthcare has been like a cottage industry but that is beginning to change.”
    In this environment, pharma companies must either deliver innovation of such clear value that it justifies a premium price, or reduce costs in order to make medicines more cheaply. All of the deals of the past year have been aimed at one or both of these goals. Bankers say there are more to come. “They’re going to continue until interest rates rise or valuations become too high as the pool of available assets shrinks,” says one. “We haven’t reached that point yet.”
    Fight for domination: Three drugs vie for your medicine cabinet
    Open the average household medicine chest and the chances are there will be a product from TevaMylan or Perrigo inside. As a 
    three-way takeover battle rages among the trio, who are these companies and how did they become such powerful forces in generic drugs?
    Teva: Its roots go back 114 years, but the breakthrough came in 1967 when, during the Arab boycott, the Israeli government allowed local drugmakers to copy patent-protected foreign medicines. Teva has since grown into the world’s top generics producer, but a fifth of its $20bn annual sales comes from a branded drug — Copaxone, for multiple sclerosis.
    Mylan: Founded in West Virginia in 1961 by two army friends who sold medicines from an old Pontiac car, its annual sales are nearing $8bn. Heather Bresch, daughter of Joe Manchin, Democratic senator for West Virginia, is its chief executive. When Mylan used a $5.3bn acquisition of overseas assets from Abbott to move its tax home to the Netherlands last year, the senator said such “inversion” deals should be banned.
    Perrigo: Set up by Luther Perrigo in Michigan in 1887, sales exceeded $4bn last year. Its recent €3.6bn purchase of Omega Pharma put it among the top five over-the-counter drugmakers. Perrigo moved to low-tax Ireland in 2013 through a $8.6bn tie-up with Elan. Andrew Ward

    FT : Eurozone officials seek to bypass Varoufakis to spur Greek talks

    Eurozone officials seek to bypass Varoufakis to spur Greek talks

    A fraught eurozone meeting in Riga at the weekend has left Yanis Varoufakis, the Greek finance minister, increasingly isolated both in Brussels and in Athens as officials seek to bypass him in an effort to jump-start bailout talks.
    Greece’s dire financial position is forcing eurozone authorities to look beyond
    Mr Varoufakis to Alexis Tsipras, prime minister, much like in February when Jeroen Dijsselbloem, the Dutch finance minister who chairs the eurogroup, brokered an extension of the current bailout programme.

    According to two eurozone officials, Mr Dijsselbloem phoned Mr Tsipras from Riga in an effort to mend fences after Friday’s feisty eurogroup meeting, where Mr Varoufakis was rounded on by his eurozone colleagues.
    In a sign that Mr Varoufakis’s combative approach is prompting concern in Greece as well, a senior Athens official said the Riga meeting was likely to lead to him being sidelined as Mr Tsipras and his deputy Yannis Dragasakis take a more hands-on role.
    Amid the acrimony, differences over a new list of reforms that is to be agreed by Athens were barely discussed at the meeting, putting off indefinitely a deal to unlock access to the funds left from Greece’s €172bn bailout.
    “All the ministers told [Mr Varoufakis]: this cannot go on,” said Luis de Guindos, Spain’s finance minister.
    Mr Varoufakis shrugged off criticism from his eurozone colleagues, comparing his situation to that of US President Franklin D. Roosevelt as he pushed through the New Deal. “They are unanimous in their hatred for me and I welcome their hatred,” he tweeted.
    Some eurozone and Greek officials believe divisions between Mr Varoufakis and Mr Tsipras are deepening and that a concerted appeal to the prime minister could still produce a deal by late May, the time many feel an agreement has to be reached if any aid disbursement can be made before the current bailout expires at the end of June.
    Although there are wide differences between Athens and eurozone creditors on matters of substance the current stand-off with Mr Varoufakis is mostly on matters of process, officials said.
    Because of the new government’s vow not to return to intrusive inspections by bailout monitors, formerly known as the “troika”, Mr Varoufakis has refused to engage with mid-level negotiators on the ground in Athens and has insisted a political agreement be reached at high levels instead. Eurozone leaders have stymied the strategy, insisting a deal be struck on a new economic reform plan with monitors in Athens before any talks on releasing aid money can occur within the eurogroup.
    “There is an element of cognitive dissonance here,” said one official involved in the talks. “Varoufakis does not comprehend that at the political level one just does not negotiate every item. Other people do that.”
    A person close to the Greek government said Mr Varoufakis had become “a drag on the Syriza administration”.
    But he is unlikely to be dropped immediately by Mr Tsipras, the person said: “The time to shed this finance minister is when the interim deal with creditors has been reached and before negotiations start on a new bailout package.”
    The government is trying to find €1bn to pay pensions and subsidies this week, and will need additional cash to make payments of €880m due to the International Monetary Fund by mid-May of face a default.
    Dimitris Mardas, deputy finance minister, has managed to raise an extra €450m from the cash reserves of state-controlled entities to pay public sector salaries for the second half of April, while suspending payments due to government suppliers and value-added tax returns to exporters.
    So far, mayors across the country have refused to comply with a decree approved by parliament on Friday forcing local authorities to deposit their cash reserves immediately with the central bank, on grounds that if Greece defaults the funds will be permanently lost.
    “We coped in February and March thanks to improved revenue inflows and payment delays,” said Mr Dragasakis. “But this situation can’t continue — it will trigger recession, and society can’t handle more recession, more unemployment and more austerity.”

    (Reuters) Atlantia interested in Nice airport; not looking at Kansai airport

    Atlantia interested in Nice airport; not looking at Kansai airport

    Atlantia, the listed Italian holding company, is interested in the privatization of the France-based Nice airport, a newswire reported.

    A Reuters report quoted Atlantia's Chief Executive Giovanni Castellucci who was answering questions during a shareholders' meeting held on 24 April. He said Atlantia has all the means to be an active player in the deal, the article noted.

    However, the company is not interested in the Kansai airport privatization, the item added.

    Previously, an announcement by Japan-based New Kansai International Airport in December 2014 had noted that Atlantia was one of 11 foreign companies that had passed the pre-qualification process for the operating rights of two Japanese airports, located in Osaka Prefecture.

    (Irish Independant) Decision on €1.4bn takeover of Aer Lingus set to drag into M

    Decision on €1.4bn takeover of Aer Lingus set to drag into May
    A decision by the Government on the future of Aer Lingus now looks set to be delayed until May, with no signs that the Cabinet is due to consider the issue at its meeting next Tuesday.

    It had been anticipated that the Government might have made a decision by next week on the potential sale of the State's 25.1pc stake in Aer Lingus to IAG.
    Aer Lingus holds its annual general meeting next Friday, while IAG also releases first quarter results next Thursday.
    It appears that neither company will now be in a position to provide any meaningful update to shareholders at the events, despite the possible €1.4bn takeover.
    However, it is not clear at this stage whether a report being prepared for Transport Minister Paschal Donohoe by a steering group has even been completed.
    Mr Donohoe will use that report to brief his Cabinet colleagues in advance of the Government making a decision on whether or not to sell the State's Aer Lingus stake.
    However, Aer Lingus unions also expect to be briefed by Department of Transport in advance of any decision being made.
    The looming bus strike and other political issues may have downgraded Aer Lingus as a priority issue on the Government's agenda for the next couple of weeks.
    Mr Donohoe has insisted on numerous occasions that he and the Government won't be rushed into making a decision on Aer Lingus, but at the same time has said he does not want the issue to drag on. Should the Government decide to sell, a Dail vote is needed before a disposal of the Aer Lingus stake can be formally approved.
    But if the Government rejects the IAG takeover approach, the British Airways and Iberia owner, which is headed by Willie Walsh, will have to decide if it will pursue majority control of Aer Lingus. Such an option could see it attempt to buy all but the Government's stake in the airline.
    One senior UK equity analyst, who did not wish to be named, told the Irish Independent that such an approach would be risky for IAG.
    He said that a takeover suitor would normally only opt to acquire a majority of a takeover target in order to prevent a potential rival bidder from muscling in, and in the hope of persuading the minority shareholder to sell out later.
    "Given the absence of other bidders, and the risks from a blocking minority, the risk might not be worth it," the analyst said.
    IAG has also said its takeover offer will be predicated on securing an agreement from Ryanair to sell its near 30pc stake in Aer Lingus to the company.
    The Department of Transport chairs the steering group preparing the report on the IAG takeover approach.
    The steering group includes executives from Credit Suisse, law firm McCann Fitzgerald, and IBI Corporate Finance.
    Irish Independent

    WSJ : Ten Years of the Airbus A380, but Demand Remains Soft

    Ten Years of the Airbus A380, but Demand Remains Soft
    Jet sales chief John Leahy sees strong demand for superjumbo from 2020

    LONDON—Airbus GroupNV on Monday celebrates the 10-year anniversary of the A380 superjumbo’s first flight. The European plane maker so far has had little to cheer about, though, as it struggled to win sales for its flagship plane.

    Development and production delays, a deep financial crisis and changes in airline preferences have stymied Airbus’s efforts to sell the world’s biggest airliner.

    Almost as many buyers have decided not to introduce into their fleets some or all of the A380s they ordered as those that have stuck to their commitments. About a dozen airlines have walked away or delayed delivery of A380 jets. Still, others, such as Emirates Airline and Singapore Airlines Ltd., have been big customers.

    When the company embarked on building the jet in 2000, Airbus bet that over the next 20 years, it would win half the market for very large aircraft, which it estimated at around 1,550 planes. Airbus to date has booked 317 A380 orders, of which 158 have been delivered.

    “The A380 was always a small market, but it’s a growing market,” Airbus’s chief operating officer for customers, John Leahy, said in an interview.

    Orders in hand are roughly in line with what Airbus expected, after taking into account that a planned larger version of the A380, and a freighter offshoot, were never built, Mr. Leahy said. Airbus scrapped those derivatives when the program fell years behind schedule and ran over cost.

    Rival Boeing Co. also has struggled to win sales for its 747-8, the direct competitor to the A380. It has had to curtail output, though the Chicago-based plane maker had lower ambitions than Airbus.

    A380 buyers that no longer are onboard with taking the plane include Virgin Atlantic Airways, the airline founded by Richard Branson; International Lease Finance Corp., one of the world’s largest leasing companies, now owned by AerCap Holdings NV; and India’s Kingfisher Airlines Ltd. A deal with Japan’s Skymark was canceled last year over payment concerns.

    Deutsche Lufthansa AG and Air France-KLM SA, have said they wouldn’t take the number they once planned. Orders from FedEx, the world’s largest cargo airline, and United Parcel Service Inc. died when the freighter was canceled.

    The A380 “from the beginning wasn’t super-efficient,” said Adam Pilarski, senior vice president at aviation consultancy Avitas. “It’s big, old technology.”

    Having given large price discounts to the A380’s first customers and those that bought large numbers, which is typical in the aviation industry, Airbus now has to try to sell A380s at high prices, he said, hampering efforts to win new deals. A380s carry a price tag of $428 million, though customers usually pay less.

    Airbus Chief Financial Officer Harald Wilhelm in December suggested the A380 could go out of production around the end of the decade unless orders pick up. Since then, however, Airbus officials have been at pains to say the project won’t be abandoned.

    Airbus spent $15 billion to develop the plane and, before costs rose, hoped to reach break-even on the program after 250 deliveries. It now has promised investors that A380s being delivered from this year will no longer lose money, though executives have ceased talking about making a profit on the program.

    Mr. Leahy said the A380 will enjoy “good, solid growth going forward.” Airbus should be able to sell about as many jets this year as the roughly 30 A380 it plans to deliver, he said.

    It has been almost three years since Airbus won an A380 order from a new airline customer, though Emirates Airline, the plane’s biggest buyer, ordered 50 more in 2013. Lessor Amedeo ordered 20 in a deal completed last year, though it has yet to announce any airlines that will take the plane and has delayed its first delivery.

    Mr. Leahy said “the market will remain a little bit soft for the next couple of years,” though he is optimistic A380 demand will show “very strong growth” from 2020 as Asian traffic increases and airports reach capacity limits forcing airlines to use bigger planes.

    The A380 has proved popular with passengers even as airline buyers remained concerned about making money with the plane. To boost the A380’s economic appeal, Airbus has increased the advertised average seat count on the plane to 544 passengers from 525. More seats mean lower unit costs, which is a closely watched measure by airlines when they decide what plane to buy.

    Mr. Leahy said some airlines are showing interest in a stretched version that could seat far more passengers.

    (BFW) Deutsche Bank First-Quarter Net Profit EU544m Vs EU1.08b


    Deutsche Bank First-Quarter Net Profit EU544m Vs EU1.08b
    2015-04-26 13:11:48.567 GMT


    By Dalia Fahmy
    (Bloomberg) --Deutsche Bank 1Q net revenue EU10.4b vs
    EU8.39b, bank said in statement today.
    * Deutsche Bank says profit hurt by 1Q litigation expenses of
    EU1.5b
    * 1Q pretax profit EU1.48b vs EU1.68B

    For Related News and Information:
    First Word scrolling panel: FIRST<GO>
    First Word newswire: NH BFW<GO>

    To contact the reporter on this story:
    Dalia Fahmy in Berlin at +49-30-70010-6217 or
    dfahmy1@bloomberg.net
    To contact the editor responsible for this story:
    Andrew Blackman at +49-30-70010-6223 or
    ablackman@bloomberg.net

    FT : UK government warns BP over potential takeover

    UK government warns BP over potential takeover

    The British government has told BP it would oppose any potential takeover of the company, which was seriously weakened by the huge bill incurred after the Gulf of Mexico Deepwater Horizon disaster five years ago.
    Amid wider consolidation in the energy sector, triggered by the sharp fall in oil prices, Downing Street has informed BP and senior City figures that it wants the group to remain a British industrial champion with global reach.

    Prime Minister David Cameron has long presented Britain as a welcoming destination for foreign investment, but his government has made it clear that it would not remain neutral if the company were the target of a foreign takeover.
    Analysts have in the past linked ExxonMobil, the world’s largest non-state oil company, to a possible move on BP. But British officials have told the Financial Times that Number 10 would be “sceptical” about any takeover — even if it involved Royal Dutch Shell, the Anglo-Dutch oil major — because it wants Britain to have two big global oil companies.
    BP declined to comment on whether the UK government had discussed the issue with the company. But Number 10 said: “The government talks to a wide range of UK businesses, as you would expect. It is in the UK’s interest to have British companies competing and succeeding at home and abroad.”
    Westminster officials admit that the UK would have few formal powers to block a bid, but a senior City figure briefed on the government’s thinking said: “They would make their opposition so clear that any foreign bidder would be deterred from actually making a bid.”
    Successive Labour and Conservative governments have pursued a laissez-faire approach to takeovers, but both parties toughened their stance last year following public, political and business concern over a bid by Pfizer for AstraZeneca. The US drugs company eventually dropped the offer for its Anglo-Swedish rival.
    BP has many assets that could interest Exxon, but the US company is seen as being unlikely to launch a bid, partly because of the political opposition it would encounter. The uncertainty BP faces over the final cost of its 2010 oil spill in the Gulf of Mexico, as well as its exposure to Russia through its stake in the state-controlled oil company Rosneft, would also deter the US group.
    Rex Tillerson, Exxon’s chief executive, has been critical of practices at BP that he suggested contributed to the disaster, suggesting that integrating the two companies could be difficult.
    Gallic gesture to keep the British in BP
    The sign for a BP filling station in Westminster on February 1, 2011 in London, England. BP has reported a loss for 2010 of 3.1bn GBP, this is the first time the oil giant has made an annual loss since 1992. This compares with a profit of 8.6bn GBP for BP in 2009. The dramatic difference can be largely attributed to the 25.3bn GBP set aside by the company for charges relation to the Gulf of Mexico oil spill last year.

    Analysts and bankers say Exxon is also wary of overpaying for acquisitions, following criticism that it paid too much for XTO Energy, the US shale gas and oil company it bought for $41bn, including debt, in 2009.
    Bob Dudley, BP chief executive, this week said the energy group had no appetite for a megamerger similar to those that reshaped the oil industry in the 1990s. “I’m not sure big is absolutely seen as beautiful,” he told a conference in Houston. “We’ve got a good portfolio, I like our portfolio.”
    He added: “I don’t see the forces at work for lots of consolidation unless the oil price stays down for some time.”
    The vulnerability of BP to a takeover has been discussed at a senior level in Whitehall since the Deepwater Horizon disaster, when an explosion on a rig working under contract for the company killed 11 men and triggered the worst offshore oil spill in US history.
    BP is still counting the cost of the disaster. It has so far provided $43.5bn over the spill, but that includes only $3.5bn for the Clean Water Act penalty, and nothing for the possible natural resource damages.
    The cost of the company’s settlement for the individuals and businesses affected by the spill is also expected to end up significantly greater than the $9.9bn included in its provisions.

    WSJ : Volkswagen Chairman Ferdinand Piech Resigns

    Volkswagen Chairman Ferdinand Piech Resigns

    Piech’s wife also announces resignation from ‘all mandates’ within German auto maker

    FRANKFURT—The powerful chairman of Volkswagen AG unexpectedly resigned Saturday, opening a new period of uncertainty for the automotive giant just weeks after he threw the company into a management crisis by withdrawing his support for VW’s chief executive.

    Ferdinand Piech “has announced his resignation with immediate effect from his position as Chairman as well as member of the Supervisory Board, as well as all other mandates within the Volkswagen Group,” said the Wolfsburg-based company.

    The statement said that Mr. Piech’s wife Ursula had also announced her resignation “from all mandates within the Volkswagen Group.”

    “The deputy Chairman of the Supervisory Board, Berthold Huber, will temporarily assume leadership of the Board until the election of a new Chairman,” said the firm.

    For the past two weeks, Mr. Piech had been in open conflict with Chief Executive Martin Winterkorn, though late this week had voiced support for him.